This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Psychiatry  • Depression  • Psychopharmacology  • Suicide  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

William M. Lydiatt, MD; David Denman, MD; Dennis P. McNeilly, PsyD; Susan E. Puumula, MS; William J. Burke, MD

Arch Otolaryngol Head Neck Surg. 2008;134(5):528-535.

Objective  To determine whether prophylactic treatment with the antidepressant citalopram hydrobromide, compared with placebo, could prevent major depressive disorder in patients undergoing therapy for head and neck cancer (HNC).

Design  Prospective, randomized, placebo-controlled trial.

Setting  Academic medical center.

Patients  Thirty-six subjects were randomized, and 23 completed the study.

Interventions  Subjects were randomized to receive 40 mg of citalopram hydrobromide or matching placebo (hereinafter, citalopram group and placebo group, respectively) for 12 weeks with a final visit at 16 weeks.

Main Outcome Measures  The Hamilton Depression Rating Scale, psychiatric interview, and the University of Washington Quality of Life (UW-QOL) and Clinician Global Impression–Severity (CGI-S) scales.

Results  The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were 5 of 10 (50%) taking placebo and 2 of 12 (17%) taking citalopram (Fisher exact test, P = .17). No patients in the citalopram group became suicidal, compared with 2 in the placebo group. Global mood state at the conclusion of the study as measured by the CGI-S scale was rated as at least mildly ill in 15% of those receiving citalopram compared with 60% in the placebo group (Fisher exact test, P = .04). Quality of life, measured by the UW-QOL, deteriorated in both groups from baseline but less so in the citalopram group.

Conclusions  This study reports data from the first depression prevention trial in HNC and suggests that prophylactic treatment may decrease the incidence of depression during HNC therapy. The clinical significance of the reduction in depression was best demonstrated by the CGI-S scale, which showed a notable difference in global psychiatric and physical well-being.

Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Drs Lydiatt and Denman), Psychiatry (Drs McNeilly and Burke), and Preventative and Societal Medicine (Ms Puumula), University of Nebraska Medical Center, and Department of Otolaryngology–Head and Neck Surgical Oncology, Nebraska Methodist Hospital (Dr Lydiatt), Omaha.